Therapeutics Program

The therapeutic effectiveness of Tocotrienols (T3s) is dependent on how much is bioavailable systemically. By improving the bioavailability of T3s using the TransT3 and TPD platforms, an improvement in the efficacy of T3s in therapeutic indications should be possible.

Invictus has chosen to target two therapeutic indications with great unmet needs, MAFLD/MASH and pancreatic cancer, where T3s have shown some promising activity in animal models and also clinical studies.

Invictus currently has four prescription drug candidates with T3 as the active pharmaceutical ingredient in development:

Subscribe to our newsletter

Copyright © Invictus Therapeutics Ltd. All Rights Reserved.
TOP